MediciNova said that it has tested a number of intranasal SARS-CoV-2 vaccine prototypes using a viral vector technology platform from Mie University and BioComo and has identified several candidates that it plans to advance. BioComo’s BC-PIV vaccine carrier is based on recombinant human parainfluenza virus 2 (hPIV2) vectors.
According to MediciNova, the intranasal vaccine candidates have demonstrated that they can elicit an immune response against the SARS-CoV-2 virus in a mouse model. The company said that it is moving ahead with in vivo studies and that preparations for manufacturing of clinical trial supplies of the candidates are underway.
MediciNova President and CEO Yuichi Iwaki commented, “We are very pleased to confirm that we now have multiple COVID-19 vaccine prototypes that induced a strong antibody response against the SARS-CoV-2 spike protein after administration of only one intranasal dose. This is a critical step in our development of an effective vaccine. We look forward to reporting additional results as soon as possible.”
Read the MediciNova press release.
